Evidence map›Paper›PMID 22179131›Full record

ArticleMedical microbiology and immunology2012

Seroprevalence study in forestry workers from eastern Germany using novel genotype 3- and rat hepatitis E virus-specific immunoglobulin G ELISAs.

Paul Dremsek, Jürgen J Wenzel, Reimar Johne, Mario Ziller, Jörg Hofmann, Martin H Groschup, Sandra Werdermann, Ulrich Mohn, Silvia Dorn, Manfred Motz and 3 more

Open access · bronzeAbstract readEvaluation Study
PubMed Publisher
In one paragraph

Article in Medical microbiology and immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed, 3 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 3 syntheses or guidelines pooled it, 155 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Extrahepatic Replication and Genomic Signatures of the Hepatitis E Virus in the Kidney.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Trial
  5. Review
  6. Article
  7. Article
  8. Prevalence ofJHEP reports : innovation in hepatology · 2025
    Article
  9. Article
  10. Rat hepatitis E virusEmerging microbes & infections · 2024
    Article
  11. Article
  12. Rat hepatitis E virus (Emerging microbes & infections · 2024
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Microorganisms · 2023
    Review
  20. Article

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Paul DremsekFriedrich-Loeffler-Institut, Federal Research Institute for Animal Health, OIE Collaborating Centre for Zoonoses in Europe, Institute for Novel and Emerging Infectious Diseases, Südufer 10, 17493, Greifswald-Insel Riems, Germany.
Jürgen J Wenzel
Reimar Johne
Mario Ziller
Jörg Hofmann
Martin H Groschup
Sandra Werdermann
Ulrich Mohn
Silvia Dorn
Manfred Motz
Marc Mertens
Wolfgang Jilg
Rainer G Ulrich
Friedrich-Loeffler-Institut · DEInstitute of Medical Microbiology and Hygiene · DECharité - Universitätsmedizin Berlin · DEFederal Institute for Risk Assessment · DEInstitut für Soziale Arbeit · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis E virus (HEV) is the causative agent of an acute self-limiting hepatitis in humans. In industrialized countries, autochthonous cases are linked to zoonotic transmission from domestic pigs, wild boar and red deer. The main route of human infection presumably is consumption of contaminated meat. Farmers, slaughterers and veterinarians are expected to be risk groups as they work close to potentially infected animals. In this study, we tested four Escherichia coli-expressed segments of the capsid protein (CP) of a German wild boar-derived HEV genotype 3 strain for their diagnostic value in an indirect immunoglobulin G (IgG) ELISA. In an initial validation experiment, a carboxy-terminal CP segment spanning amino acid (aa) residues 326-608 outperformed the other segments harbouring aa residues 112-608, 326-660 and 112-335. Based on this segment, an indirect ELISA for detection of anti-HEV IgG antibodies in human sera was established and validated using a commercial line immunoassay as reference assay. A total of 563 sera from forestry workers of all forestry offices of Brandenburg, eastern Germany and 301 sera of blood donors from eastern Germany were surveyed using these assays. The commercial test revealed seroprevalence rates of 11% for blood donors and 18% for forestry workers. These rates are in line with data obtained by the in-house test (12 and 21%). Hence, the in-house test performed strikingly similar to the commercial test (sensitivity 0.9318, specificity 0.9542). An initial screening of forestry worker and blood donor sera with a corresponding CP segment of the recently discovered Norway rat-associated HEV revealed several strong positive sera exclusively in the forestry worker panel. Future investigations have to prove the performance of this novel IgG ELISA in large-scale seroepidemiological studies. In addition, the observed elevated seroprevalence in a forestry worker group has to be confirmed by studies on groups of forestry workers from other regions. The epidemiological role of ratHEV in human disease should be assessed in a large-scale study of risk and non-risk groups.

Indexed as

AgricultureForestryOccupational ExposureAnimalsClinical Laboratory TechniquesEnzyme-Linked Immunosorbent AssayFemaleGenotypeGermanyHepatitis AntibodiesHepatitis EHepatitis E virusHumansImmunoglobulin GMaleRatsHepatitis AntibodiesImmunoglobulin G

Identifiers

PMID22179131
OpenAlexW2131020874

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.